Monash University Victoria Australia – Micromon Genomic, Biotechnology and Diagnostics Division completed intensive independent 3 year testing protocol on its formula and composition under strict quality standard examination guidelines known as JIS Z 2801: 2000E an antibacterial activity and efficacy test.
RIDOV was tested against three significant bacteria mediums Golden Staph, Vancomycin-Resistant Enterococci (VRE), Methicillin-resistant Staphylococcus aureus (MRSA) commencing in 2011 and concluding 2013.
Conducted by Dr Kylie Wilson (Senior Technical Officer) and Dr Kunkun Zhang (Technical Officer) of MICROMON located at Building 75, Monash University, 3800 Clayton Campus, Wellington Road, and Clayton VICTORIA. Monash University Victoria’s clinical trials found RIDOV delivered a highly effective kill rate of 99.99% offering a protection cycle of 72 hours.
Further independent testing using the same anti-bacterial activity and efficacy test JIS Z 2801: 2000E. was completed in 11th August 2014 by the ams Laboratories Pty Ltd (ams) located 8 Racheal Close Silverwater NSW 2128 confirmed Monash University 2011/13 findings concluding that RIDOV kills Golden Staph, VRE, MRSA 99.99%.
Further testing was completed for E-coli on the 27th October 2014 by ams Laboratories who certified that RIDOV kills E-coli 99.99% offering the same protection cycle of 72 hours.
We will continue to test for new strains of bacteria as part of our continued improvements and the fight against SUPERBUGS.
The following documents are test evidence.
Click the links below to download RIDOV test results.